| Description | PHI-101 is an orally available and selective checkpoint kinase 2 (Chk2) inhibitor for the study of refractory acute myelogenous leukemia (AML) and ovarian cancer. |
| Synonyms | PHI101, PHI 101 |
| molecular weight | 386.44 |
| Molecular formula | C19H19FN4O2S |
| CAS | 2127107-15-5 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 80 mg/mL (207.02 mM), Sonication is recommended. |
| References | 1. Nam K Y, et al. PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia[J]. Blood, 2020, 136: 28. |